rosiglitazone has been researched along with c-peptide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 19 (82.61) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomis, R; Jones, NP; Patwardhan, RN; Squatrito, S; Wolffenbuttel, BH | 1 |
| Deacon, LF; Jones, NP; Nolan, JJ; Patwardhan, R | 1 |
| Grunberger, G; Miller, E; Patwardhan, R; Phillips, LS; Rappaport, EB; Salzman, A | 1 |
| Anderson, RJ; Patel, J; Rappaport, EB | 1 |
| Beck-Nielsen, H; Henriksen, JE; Hother-Nielsen, O; Poulsen, MK | 1 |
| James, R; Kerenyi, Z; Samer, H; Stewart, M; Yan, Y | 1 |
| Bell, DS; Ovalle, F | 1 |
| Bullock, M; Gaillard, T; Kaplow, J; Osei, K; Schuster, D | 1 |
| Ahn, CW; Cha, BS; Choi, SH; Huh, KB; Kim, DJ; Kim, KR; Kim, SK; Kim, YM; Lee, HC; Lim, SK | 1 |
| Fan, SC; He, CT; Hsieh, CH; Hung, YJ; Kuo, SW; Lee, CH; Lee, JT; Pei, D; Sheu, WH; Wu, LY | 1 |
| Haas, T; Perusicová, J | 1 |
| Björnholm, M; Chibalin, AV; Hällsten, K; Heinonen, OJ; Karlsson, HK; Lönnqvist, F; Nuutila, P; Tsuchida, H; Virtanen, KA; Zierath, JR | 1 |
| Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Pinaire, JA; Tan, MH; Zagar, AJ | 1 |
| Raskin, P; Strowig, SM | 1 |
| Abbasi, F; Chu, JW; Kim, SH; Lamendola, C; McLaughlin, TL; Polonsky, KS; Reaven, GM | 1 |
| Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J | 1 |
| Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ | 1 |
| Brophy, S; Brunt, H; Davies, H; Mannan, S; Williams, R | 1 |
| Blanchard, J; Eismann, T; Galloway, E; Huber, N; Kuboki, S; Lentsch, AB; Schuster, R; Shin, T; Zingarelli, B | 1 |
| Huang, G; Li, X; Lin, J; Yang, Z; Zhou, Z | 1 |
| Erem, C; Fidan, E; Karahan, C; Kocak, M; Onder Ersoz, H; Yilmaz, H; Yilmaz, M | 1 |
| El Ouaamari, A; Hu, J; Kawamori, D; Kulkarni, RN; Meyer, J; Smith, DM; Welters, HJ | 1 |
| Brooks-Worrell, BM; Palmer, JP | 1 |
1 review(s) available for rosiglitazone and c-peptide
| Article | Year |
|---|---|
Interventions for latent autoimmune diabetes (LADA) in adults.
Topics: Adult; Autoimmune Diseases; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
16 trial(s) available for rosiglitazone and c-peptide
| Article | Year |
|---|---|
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Europe; Female; Fructosamine; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2000 |
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glycated Hemoglobin; Glycolysis; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2003 |
Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Fatty Acids, Nonesterified; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones; Triglycerides | 2004 |
Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes.
Topics: Adiponectin; Adult; Black or African American; Blood Glucose; Blood Pressure; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Intercellular Signaling Peptides and Proteins; Islets of Langerhans; Lipids; Longitudinal Studies; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2004 |
Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Korea; Male; Middle Aged; Patient Selection; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Chi-Square Distribution; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sex Factors; Single-Blind Method; Thiazolidinediones; Treatment Outcome | 2005 |
Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Thiazolidinediones | 2005 |
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Topics: Aged; Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
The effect of rosiglitazone on overweight subjects with type 1 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Body Size; C-Peptide; Diabetes Mellitus, Type 1; Double-Blind Method; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Obesity; Placebos; Rosiglitazone; Thiazolidinediones; Weight Gain | 2005 |
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2005 |
Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus.
Topics: Adult; C-Peptide; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Humans; Interleukin-6; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.
Topics: Adult; Aged; Autoantibodies; Autoimmunity; C-Peptide; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Immunosuppression Therapy; Interferon-gamma; Interleukin-12; Islets of Langerhans; Male; Middle Aged; PPAR gamma; Rosiglitazone; T-Cell Antigen Receptor Specificity; T-Lymphocytes; Thiazolidinediones | 2013 |
6 other study(ies) available for rosiglitazone and c-peptide
| Article | Year |
|---|---|
Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes.
Topics: Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Regression Analysis; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
[Rosiglitazon in treatment of Type II diabetes mellitus--experience of diabetologists in the Czech Republic. Part I: compensation of diabetes, sugar metabolism].
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Metabolic Clearance Rate; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinical; Glioma; Humans; Hypoglycemic Agents; Inflammation; Insulin; Intercellular Adhesion Molecule-1; Kidney; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Macrophages; Male; Mice; Mice, Inbred C57BL; Monocytes; PPAR gamma; Prostaglandin D2; Protein Transport; Rosiglitazone; Thiazolidinediones; Transcription Factor RelA; Troglitazone; Tumor Necrosis Factor-alpha | 2006 |
Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice.
Topics: Animals; C-Peptide; E1A-Associated p300 Protein; Gene Expression Regulation; Hepatocytes; Liver; Liver Diseases; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Prostaglandin D2; Reperfusion Injury; Retinoid X Receptor alpha; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone promotes PPARγ-dependent and -independent alterations in gene expression in mouse islets.
Topics: Animals; Blood Glucose; C-Peptide; Diet, High-Fat; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Islets of Langerhans; Mice; Mice, Transgenic; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2012 |